Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Nov 4, 2019

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
Oct 31, 2019

Sanofi Q3 well on track
- Video 1
- Photos 4
Oct 29, 2019

Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019
Oct 24, 2019

Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Oct 22, 2019

Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease

-Study Did Not Achieve Primary Endpoint Due to High Placebo Effect-

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.